2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-131870
    GX-201
    		Inhibitor 98.89%
    GX-201 is a selective NaV1.7 inhibitor, with an IC50 of <3.2 nM for hNaV1.7.
    GX-201
  • HY-110325
    PF-04885614
    		Inhibitor
    PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment.
    PF-04885614
  • HY-B1704
    Nisoxetine
    		Inhibitor 98.56%
    Nisoxetine is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
    Nisoxetine
  • HY-108506
    Licarbazepine
    		Inhibitor 99.77%
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine
  • HY-B0495R
    Lamotrigine (Standard)
    		Inhibitor
    Lamotrigine (Standard) is the analytical standard of Lamotrigine. This product is intended for research and analytical applications. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine (Standard)
  • HY-B0246R
    Carbamazepine (Standard)
    		Inhibitor
    Carbamazepine (Standard) is the analytical standard of Carbamazepine. This product is intended for research and analytical applications. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.
    Carbamazepine (Standard)
  • HY-105283
    PF 04531083
    		Antagonist 98.96%
    PF 04531083 is an orally active and selective NaV1.8 blocker with an IC50 of 0.7 μM. PF 04531083 is a blood-brain barrier (BBB) penetrant compound. PF 04531083 can be used for the research of respiratory system and neuropathic/inflammatory pain.
    PF 04531083
  • HY-B1551
    Benzonatate
    		Inhibitor 98.96%
    Benzonatate (Benzononatine) is an orally active and non-narcotic peripheral antitussive agent. Benzonatate is a reversible voltage-gated Na+ channels inhibitor. Benzonatate dampens the activity of cough stretch receptors.
    Benzonatate
  • HY-N1847
    3'-Methoxydaidzein
    		Inhibitor 99.67%
    3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels.
    3'-Methoxydaidzein
  • HY-119980
    Fluphenazine
    		Inhibitor 98.70%
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine
  • HY-B0185AS
    Lidocaine-d10 hydrochloride
    		Inhibitor 99.55%
    Lidocaine-d10 (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia.
    Lidocaine-d<sub>10</sub> hydrochloride
  • HY-19958
    XEN907
    		Inhibitor 98.74%
    XEN907 is a potent and spirooxindole blocker of NaV1.7, with an IC50 of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain.
    XEN907
  • HY-17612
    Evenamide
    		Inhibitor
    Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
    Evenamide
  • HY-B1288
    Oxybuprocaine hydrochloride
    		Inhibitor 99.93%
    Oxybuprocaine hydrochloride (Benoxinate hydrochloride) reversibly blocks sodium channels and prevents propagation of painful nerve impulses in the cornea, conjunctiva, and sclera. Oxybuprocaine hydrochloride is used especially in ophthalmology and otolaryngology.
    Oxybuprocaine hydrochloride
  • HY-N6868
    Dimethyl lithospermate B
    		Agonist 99.77%
    Dimethyl lithospermate B (dmLSB) is a selective Na+ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP).
    Dimethyl lithospermate B
  • HY-W090942
    Z-Gly-Gly-Phe-OH
    		Inhibitor 99.46%
    Z-Gly-Gly-Phe-OH is a substrate for pepsin and thermolysin. Z-Gly-Gly-Phe-OH has an IC50 of 15.8 μM for open sodium channels under pepsin catalysis. Z-Gly-Gly-Phe-OH forms peptide bonds with amine components (such as H-Leu-NHPh) through enzyme-catalyzed condensation reactions, and is active as an intermediate in peptide synthesis.
    Z-Gly-Gly-Phe-OH
  • HY-B0527AR
    Amitriptyline hydrochloride (Standard)
    		Inhibitor
    Amitriptyline hydrochloride (Standard) is the analytical standard of Amitriptyline hydrochloride (HY-B0527A). This product is intended for research and analytical applications. Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity.
    Amitriptyline hydrochloride (Standard)
  • HY-103623
    PF-05241328
    		Inhibitor 98.08%
    PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM.
    PF-05241328
  • HY-P1218B
    Phrixotoxin 3-NH2 TFA
    		Inhibitor 98.63%
    Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
    Phrixotoxin 3-NH2 TFA
  • HY-130335
    Encainide
    		Inhibitor 99.89%
    Encainide (MJ9067) is an antiarrhythmic agent with class IC activity. Encainide blocks voltage-dependent potassium channels. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research.
    Encainide
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.